Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review.
Mohammad Ebad Ur RehmanAsmi ChattarajKarun NeupaneAbdul RafaeSajeel SaeedJawad BasitAtif IbrahimJack KhouriSudipto MukherjeeFaiz AnwarPublished in: European journal of haematology (2022)
Results from a randomized controlled trial and an extension study highlighted the efficacy and long-term safety of siltuximab for iMCD; other trials showed tocilizumab to be a suitable alternative. A recent trial reported high response rates with thalidomide in iMCD patients. Promising results were reported for bortezomib in relapsed/ refractory MCD. For human herpesvirus-8 (HHV8)-associated MCD, rituximab along with doxorubicin therapy followed by maintenance with zidovudine and valganciclovir is the most effective therapy. A single-arm trial has highlighted the potential role of tocilizumab in HHV8-MCD. Data for these regimens are limited and mostly comprise nonrandomized trials. Further research on emerging agents could have a major impact on the treatment of this rare disease.
Keyphrases
- rheumatoid arthritis
- newly diagnosed
- end stage renal disease
- study protocol
- clinical trial
- diffuse large b cell lymphoma
- multiple myeloma
- chronic kidney disease
- endothelial cells
- acute myeloid leukemia
- randomized controlled trial
- phase ii
- juvenile idiopathic arthritis
- hodgkin lymphoma
- stem cells
- combination therapy
- electronic health record
- bone marrow
- big data
- cell therapy
- patient reported